Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03595228 · ClinicalTrials.gov registry record · Phase 2
BN Brachyury and Radiation in Chordoma
A Phase 2 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT03595228 is a Phase 2 study that has completed, run by Bavarian Nordic. The registered enrollment target is 29 participants.
The verdict
NCT03595228, a Phase 2 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The goal of this study is to determine if the combination of BN-Brachyury plus radiation therapy can induce objective radiographic response rate (ORR) in patients, using a Simon 2-stage optimal design. In stage 1, a minimum of threshold of activity is needed to proceed to stage 2.
Interventions
- BIOLOGICAL BN-Brachyury plus radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2022-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03595228
The ClinicalTrials.gov registry entry for NCT03595228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BN-Brachyury plus radiation is the first listed.
NCT03595228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03595228 about?
NCT03595228 is a clinical study titled "BN Brachyury and Radiation in Chordoma". The goal of this study is to determine if the combination of BN-Brachyury plus radiation therapy can induce objective radiographic response rate (ORR) in patients, using a Simon 2-stage optimal design. In stage 1, a minimum of threshold of activity is needed to proceed to stage 2.
What is the current status of trial NCT03595228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2018-10-31. Estimated completion is 2022-01-25.
What interventions are being tested in trial NCT03595228?
The interventions under investigation include: BN-Brachyury plus radiation (BIOLOGICAL).
Who is sponsoring clinical trial NCT03595228?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.